CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 235 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q2 2024. The put-call ratio across all filers is 1.79 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $13,718,595 | -45.9% | 335,500 | -44.1% | 0.13% | -43.8% |
| Q1 2024 | $25,362,042 | +190.6% | 600,001 | +191.5% | 0.23% | +145.3% |
| Q4 2023 | $8,726,302 | -16.1% | 205,809 | -56.8% | 0.10% | -22.1% |
| Q3 2023 | $10,404,920 | -58.8% | 476,634 | -40.0% | 0.12% | -59.3% |
| Q2 2023 | $25,270,475 | +69.5% | 794,919 | +30.0% | 0.30% | +47.8% |
| Q1 2023 | $14,911,217 | +1.8% | 611,366 | +31.6% | 0.20% | +3.6% |
| Q4 2022 | $14,647,428 | -3.4% | 464,408 | -13.4% | 0.20% | -7.5% |
| Q3 2022 | $15,158,000 | +124.4% | 536,385 | +109.9% | 0.21% | +103.8% |
| Q2 2022 | $6,756,000 | -46.7% | 255,533 | -29.4% | 0.10% | -49.5% |
| Q1 2022 | $12,665,000 | +64.6% | 361,753 | +52.4% | 0.21% | +87.3% |
| Q4 2021 | $7,694,000 | +33.5% | 237,326 | +21.5% | 0.11% | +17.0% |
| Q3 2021 | $5,762,000 | +56.5% | 195,331 | +35.9% | 0.09% | +36.2% |
| Q2 2021 | $3,682,000 | -31.8% | 143,712 | -63.4% | 0.07% | -42.5% |
| Q1 2021 | $5,395,000 | – | 392,910 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |